Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

nucletron pty limited -

Singapur - angleščina - HSA (Health Sciences Authority)

h & f - capsule

Singapur - angleščina - HSA (Health Sciences Authority)

kim sin medicine manufactory pte. ltd. - capsules

Združene države Amerike - angleščina - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see overdosage) . controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride (see precautions: information for patients, and dosage and administration sections). all solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

abbott medical australia pty ltd -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

integrated sciences pty ltd - ct869 - clinical chemistry autoimmune ivds - ivds that are intended to be used for the qualitative and or quantitative determination of autoimmune markers in a clinical specimen. each ivd is intended to be used by a medical laboratory scientist. techniques used include: elisa, indirect immunofluorescence

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

integrated sciences pty ltd - ct869 - clinical chemistry autoimmune ivds - ivds that are intended to be used for the qualitative and or quantitative determination of autoimmune markers in a clinical specimen. each ivd is intended to be used by a medical laboratory scientist. techniques used include: elisa, indirect immunofluorescence and quickcard.